9.10.1 ABSTRACT: CLINICAL PROTOCOL AND DATA MANAGEMENT {Clinical Trials Office) Director, Scott Baker. M.D., M.S. The mission of the University of Minnesota Cancer Center (UMCC) Clinical Protocol and Data Management Shared Resource (hereafter referred to;as the Clinical Trials Office [CTO]) is to provide a resource to UMCC investigators allowing them to perform high quality clinical research that insures validity and integrity of data and fulfiHs all NCI, federal, and local regulatory requirements. The CTO's centralized services enable the investigator to initiate and participate in a wider spectrum of clinical research activities, with the primary focus on supporting the development of investigator-initiated novel therapeutic strategies that arise out of the various UMCC research programs. In addition, the CTO is a center of excellence for clinical trial planning, execution and training. The CTO provides a centralized location for the development, administration and conduct all cancer protocols including investigator initiated IND/IDE trials and all related correspondences with regulatory agencies including the University of Minnesota Institutional Review Board (IRB), National Institutes of Health (NIH) and U.S. Food and Drug Administration (FDA). The Clinical Trial Office provides four major distinct functions: 1) Clinical Trial Operations and Management, 2) Regulatory Affairs 3) Quality Control/Assurance 4) Systems Management and Resources. In conjunction with the principal investigator the CTO staff channel the development of a new clinical trial from protocol design, protocol review and approval, research staff education, study implementation, data collection and entry, through trial completion. The CTO supports investigator-initiated therapeutic and non-therapeutic studies which may be sponsored by the NCI, NHLBI or other NIH branches, in addition to cooperative group and industry studies. From September 1, 2006 to August 31,2007, more than 300 clinical trials were registered with the CTO and open to patient accrual. Of these, 29% were investigator initiated institutional trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA077598-14S1
Application #
8530557
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-02-01
Budget End
2013-01-31
Support Year
14
Fiscal Year
2012
Total Cost
$2,678
Indirect Cost
$916
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Sarver, Aaron L; Murray, Collin D; Temiz, Nuri A et al. (2016) MYC and PVT1 synergize to regulate RSPO1 levels in breast cancer. Cell Cycle 15:881-5
Diep, Caroline H; Knutson, Todd P; Lange, Carol A (2016) Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming. Mol Cancer Res 14:141-62
Yun, Young Sung; Kim, Kwan Hyun; Tschida, Barbara et al. (2016) mTORC1 Coordinates Protein Synthesis and Immunoproteasome Formation via PRAS40 to Prevent Accumulation of Protein Stress. Mol Cell 61:625-39
Yan, Y; Hanse, E A; Stedman, K et al. (2016) Transcription factor C/EBP-β induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17-92 cluster in differentiating AML cells. Cell Death Differ 23:1232-42
Beura, Lalit K; Hamilton, Sara E; Bi, Kevin et al. (2016) Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532:512-6
Than, B L N; Linnekamp, J F; Starr, T K et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87
Struntz, Nicholas B; Harki, Daniel A (2016) Catch and Release DNA Decoys: Capture and Photochemical Dissociation of NF-κB Transcription Factors. ACS Chem Biol 11:1631-8
Knorr, David A; Wang, Hongbo; Aurora, Mukta et al. (2016) Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 22:825-33
Glasgow, Michelle; Vogel, Rachel Isaksson; Burgart, Jennifer et al. (2016) Long term follow-up of a phase II trial of multimodal therapy given in a "sandwich" method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol Res Pract 3:6
Felices, Martin; Lenvik, Todd R; Davis, Zachary B et al. (2016) Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells. Methods Mol Biol 1441:333-46

Showing the most recent 10 out of 763 publications